Diligence memo · auto-generated · as of July 2, 2026
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Abata Therapeutics, Inc. operates in Biotechnology, based in WATERTOWN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Abata Therapeutics, Inc. has raised $60M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2021-06-04.
Most recent recorded round closed around 2023-12-14.
Valuation (modeled)modeled
Provath models Abata Therapeutics, Inc. at approximately $169M (range $47M–$276M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.34× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 2.5 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 2.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 85% of Biotechnology peers (4293 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.